Close this search box.

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK.

The European Lifestars Awards are instrumental in highlighting the incredible work being carried out across the life sciences industry. This award recognizes Synaffix’s pivotal year of growth and progress as it continues to develop and commercialize its proprietary ADC technology platforms.

Synaffix’ proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies.  Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability. Together with the toxSYN™ linker-payloads, these three technologies provide developers with a “one stop” and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary, Best-in-Class ADC.

During the award qualification period (September 2021 to September 2022) Synaffix signed 5 ADC technology out-licensing deals with top tier biotech and pharma companies that come with a total combined potential value exceeding $2.5 Billion dollars, excluding the royalties payable on net sales of future products. These deals represent partnerships with companies including: Mersana Therapeutics, Genmab, Macrogenics, Kyowa Kirin and Emergence Therapeutics and comprise 5 of the 10 current partners developing ADC product candidates using Synaffix ADC technology.  Synaffix continues to build its partnered pipeline as technology out-licensing is the primary focus of its corporate strategy to deliver best-in-class targeted cancer therapeutics from partner antibodies.

“It is fantastic to be recognized by our industry peers and receive this award, following the successful achievements enabled through our collaborations this past year, and it is clear that we would not be standing here today without the continued trust and support of our partners. Our award-winning ADC platform brings significant improvements to next generation ADCs and is now being used to develop >20 different targeted cancer therapeutics across our 10 collaborations with top-tier biotech and pharma companies. This underscores the importance of collaborations across the life sciences industry to the acceleration of innovation.”

Peter van de Sande, Chief Executive Officer of Synaffix

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.